nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—Terminal insomnia—Varenicline—nicotine dependence	0.0628	0.0914	CcSEcCtD
Atomoxetine—Middle insomnia—Varenicline—nicotine dependence	0.048	0.0698	CcSEcCtD
Atomoxetine—Initial insomnia—Varenicline—nicotine dependence	0.0431	0.0627	CcSEcCtD
Atomoxetine—Abnormal behaviour—Varenicline—nicotine dependence	0.0212	0.0308	CcSEcCtD
Atomoxetine—Dysphoria—Varenicline—nicotine dependence	0.0182	0.0265	CcSEcCtD
Atomoxetine—Depressed mood—Varenicline—nicotine dependence	0.0176	0.0256	CcSEcCtD
Atomoxetine—Sinus congestion—Varenicline—nicotine dependence	0.0158	0.023	CcSEcCtD
Atomoxetine—Hostility—Varenicline—nicotine dependence	0.0142	0.0207	CcSEcCtD
Atomoxetine—Sexual dysfunction—Varenicline—nicotine dependence	0.0141	0.0204	CcSEcCtD
Atomoxetine—Suicide attempt—Varenicline—nicotine dependence	0.0139	0.0202	CcSEcCtD
Atomoxetine—Completed suicide—Varenicline—nicotine dependence	0.0134	0.0195	CcSEcCtD
Atomoxetine—Upset stomach—Varenicline—nicotine dependence	0.012	0.0175	CcSEcCtD
Atomoxetine—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.0117	0.017	CcSEcCtD
Atomoxetine—Laryngeal pain—Varenicline—nicotine dependence	0.0116	0.0168	CcSEcCtD
Atomoxetine—Menstrual disorder—Varenicline—nicotine dependence	0.0116	0.0168	CcSEcCtD
Atomoxetine—Suicidal ideation—Varenicline—nicotine dependence	0.0112	0.0163	CcSEcCtD
Atomoxetine—Mania—Varenicline—nicotine dependence	0.0108	0.0158	CcSEcCtD
Atomoxetine—Mydriasis—Varenicline—nicotine dependence	0.00988	0.0144	CcSEcCtD
Atomoxetine—Rhinorrhoea—Varenicline—nicotine dependence	0.00973	0.0141	CcSEcCtD
Atomoxetine—Aggression—Varenicline—nicotine dependence	0.00897	0.013	CcSEcCtD
Atomoxetine—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00851	0.0338	CbGpPWpGaD
Atomoxetine—NPY1R—Peptide GPCRs—OPRM1—nicotine dependence	0.00797	0.0316	CbGpPWpGaD
Atomoxetine—Blood pressure increased—Varenicline—nicotine dependence	0.00788	0.0115	CcSEcCtD
Atomoxetine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00783	0.031	CbGpPWpGaD
Atomoxetine—Abnormal dreams—Varenicline—nicotine dependence	0.00779	0.0113	CcSEcCtD
Atomoxetine—Methadone—CHRNA10—nicotine dependence	0.00757	0.529	CrCbGaD
Atomoxetine—NPY1R—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.0075	0.0297	CbGpPWpGaD
Atomoxetine—Sleep disorder—Varenicline—nicotine dependence	0.00661	0.00961	CcSEcCtD
Atomoxetine—Disorientation—Varenicline—nicotine dependence	0.00639	0.0093	CcSEcCtD
Atomoxetine—Libido decreased—Varenicline—nicotine dependence	0.00617	0.00897	CcSEcCtD
Atomoxetine—Hot flush—Varenicline—nicotine dependence	0.00612	0.00889	CcSEcCtD
Atomoxetine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00611	0.0242	CbGpPWpGaD
Atomoxetine—Menopausal symptoms—Varenicline—nicotine dependence	0.00606	0.00881	CcSEcCtD
Atomoxetine—Thirst—Varenicline—nicotine dependence	0.00601	0.00874	CcSEcCtD
Atomoxetine—Lethargy—Varenicline—nicotine dependence	0.00584	0.00849	CcSEcCtD
Atomoxetine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00568	0.00825	CcSEcCtD
Atomoxetine—Affect lability—Varenicline—nicotine dependence	0.00563	0.00818	CcSEcCtD
Atomoxetine—Psychotic disorder—Varenicline—nicotine dependence	0.00559	0.00812	CcSEcCtD
Atomoxetine—Irritability—Varenicline—nicotine dependence	0.00546	0.00794	CcSEcCtD
Atomoxetine—Urinary retention—Varenicline—nicotine dependence	0.00544	0.00791	CcSEcCtD
Atomoxetine—Mood swings—Varenicline—nicotine dependence	0.00542	0.00788	CcSEcCtD
Atomoxetine—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00527	0.0209	CbGpPWpGaD
Atomoxetine—Abdominal pain upper—Varenicline—nicotine dependence	0.00522	0.00759	CcSEcCtD
Atomoxetine—Breast disorder—Varenicline—nicotine dependence	0.00517	0.00751	CcSEcCtD
Atomoxetine—Nasopharyngitis—Varenicline—nicotine dependence	0.00512	0.00744	CcSEcCtD
Atomoxetine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00485	0.0192	CbGpPWpGaD
Atomoxetine—Abdominal discomfort—Varenicline—nicotine dependence	0.00474	0.00689	CcSEcCtD
Atomoxetine—Pollakiuria—Varenicline—nicotine dependence	0.00457	0.00664	CcSEcCtD
Atomoxetine—Erectile dysfunction—Varenicline—nicotine dependence	0.00455	0.00662	CcSEcCtD
Atomoxetine—NPY1R—GPCR ligand binding—TAS2R16—nicotine dependence	0.00454	0.018	CbGpPWpGaD
Atomoxetine—NPY1R—brain—nicotine dependence	0.00449	0.0982	CbGeAlD
Atomoxetine—Infestation—Varenicline—nicotine dependence	0.00441	0.00641	CcSEcCtD
Atomoxetine—Infestation NOS—Varenicline—nicotine dependence	0.00441	0.00641	CcSEcCtD
Atomoxetine—Depression—Varenicline—nicotine dependence	0.0044	0.00639	CcSEcCtD
Atomoxetine—Conjunctivitis—Varenicline—nicotine dependence	0.00428	0.00623	CcSEcCtD
Atomoxetine—Sinusitis—Varenicline—nicotine dependence	0.00414	0.00601	CcSEcCtD
Atomoxetine—HTR6—Monoamine GPCRs—DRD2—nicotine dependence	0.00405	0.0161	CbGpPWpGaD
Atomoxetine—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00402	0.016	CbGpPWpGaD
Atomoxetine—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00394	0.0156	CbGpPWpGaD
Atomoxetine—Hypoaesthesia—Varenicline—nicotine dependence	0.00394	0.00572	CcSEcCtD
Atomoxetine—Hallucination—Varenicline—nicotine dependence	0.00394	0.00572	CcSEcCtD
Atomoxetine—Urinary tract disorder—Varenicline—nicotine dependence	0.00391	0.00568	CcSEcCtD
Atomoxetine—Urethral disorder—Varenicline—nicotine dependence	0.00388	0.00564	CcSEcCtD
Atomoxetine—HTR1B—cardiovascular system—nicotine dependence	0.00388	0.0849	CbGeAlD
Atomoxetine—HTR1D—cardiovascular system—nicotine dependence	0.00375	0.0822	CbGeAlD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00375	0.0149	CbGpPWpGaD
Atomoxetine—Cardiac disorder—Varenicline—nicotine dependence	0.00367	0.00534	CcSEcCtD
Atomoxetine—Angiopathy—Varenicline—nicotine dependence	0.00359	0.00522	CcSEcCtD
Atomoxetine—Mediastinal disorder—Varenicline—nicotine dependence	0.00357	0.00518	CcSEcCtD
Atomoxetine—Chills—Varenicline—nicotine dependence	0.00355	0.00516	CcSEcCtD
Atomoxetine—Mental disorder—Varenicline—nicotine dependence	0.00347	0.00504	CcSEcCtD
Atomoxetine—Malnutrition—Varenicline—nicotine dependence	0.00344	0.00501	CcSEcCtD
Atomoxetine—HTR6—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00341	0.0135	CbGpPWpGaD
Atomoxetine—Flatulence—Varenicline—nicotine dependence	0.00339	0.00493	CcSEcCtD
Atomoxetine—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00338	0.0134	CbGpPWpGaD
Atomoxetine—Dysgeusia—Varenicline—nicotine dependence	0.00337	0.0049	CcSEcCtD
Atomoxetine—Back pain—Varenicline—nicotine dependence	0.00333	0.00484	CcSEcCtD
Atomoxetine—Muscle spasms—Varenicline—nicotine dependence	0.00331	0.00481	CcSEcCtD
Atomoxetine—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00331	0.0131	CbGpPWpGaD
Atomoxetine—Vision blurred—Varenicline—nicotine dependence	0.00325	0.00472	CcSEcCtD
Atomoxetine—Tremor—Varenicline—nicotine dependence	0.00323	0.00469	CcSEcCtD
Atomoxetine—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00317	0.0126	CbGpPWpGaD
Atomoxetine—Agitation—Varenicline—nicotine dependence	0.00317	0.0046	CcSEcCtD
Atomoxetine—NPY1R—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00316	0.0125	CbGpPWpGaD
Atomoxetine—HTR6—brain—nicotine dependence	0.00316	0.0691	CbGeAlD
Atomoxetine—Vertigo—Varenicline—nicotine dependence	0.0031	0.0045	CcSEcCtD
Atomoxetine—Syncope—Varenicline—nicotine dependence	0.00309	0.00449	CcSEcCtD
Atomoxetine—Palpitations—Varenicline—nicotine dependence	0.00304	0.00443	CcSEcCtD
Atomoxetine—HTR1B—midbrain—nicotine dependence	0.00303	0.0663	CbGeAlD
Atomoxetine—Loss of consciousness—Varenicline—nicotine dependence	0.00303	0.0044	CcSEcCtD
Atomoxetine—Cough—Varenicline—nicotine dependence	0.00301	0.00437	CcSEcCtD
Atomoxetine—SLC6A3—midbrain—nicotine dependence	0.003	0.0657	CbGeAlD
Atomoxetine—HTR2C—Monoamine GPCRs—DRD2—nicotine dependence	0.00299	0.0118	CbGpPWpGaD
Atomoxetine—Convulsion—Varenicline—nicotine dependence	0.00298	0.00434	CcSEcCtD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00293	0.0116	CbGpPWpGaD
Atomoxetine—Myalgia—Varenicline—nicotine dependence	0.00293	0.00426	CcSEcCtD
Atomoxetine—Arthralgia—Varenicline—nicotine dependence	0.00293	0.00426	CcSEcCtD
Atomoxetine—Chest pain—Varenicline—nicotine dependence	0.00293	0.00426	CcSEcCtD
Atomoxetine—HTR1D—midbrain—nicotine dependence	0.00293	0.0642	CbGeAlD
Atomoxetine—Anxiety—Varenicline—nicotine dependence	0.00292	0.00425	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00291	0.00423	CcSEcCtD
Atomoxetine—HTR2C—midbrain—nicotine dependence	0.0029	0.0636	CbGeAlD
Atomoxetine—Dry mouth—Varenicline—nicotine dependence	0.00287	0.00417	CcSEcCtD
Atomoxetine—Infection—Varenicline—nicotine dependence	0.00279	0.00406	CcSEcCtD
Atomoxetine—Shock—Varenicline—nicotine dependence	0.00277	0.00402	CcSEcCtD
Atomoxetine—Nervous system disorder—Varenicline—nicotine dependence	0.00276	0.00401	CcSEcCtD
Atomoxetine—SLC6A4—midbrain—nicotine dependence	0.00275	0.0603	CbGeAlD
Atomoxetine—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00275	0.0109	CbGpPWpGaD
Atomoxetine—Tachycardia—Varenicline—nicotine dependence	0.00274	0.00399	CcSEcCtD
Atomoxetine—Skin disorder—Varenicline—nicotine dependence	0.00273	0.00397	CcSEcCtD
Atomoxetine—Hyperhidrosis—Varenicline—nicotine dependence	0.00272	0.00395	CcSEcCtD
Atomoxetine—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00269	0.0107	CbGpPWpGaD
Atomoxetine—Anorexia—Varenicline—nicotine dependence	0.00268	0.0039	CcSEcCtD
Atomoxetine—HTR2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00259	0.0103	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00257	0.0102	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00256	0.00372	CcSEcCtD
Atomoxetine—Insomnia—Varenicline—nicotine dependence	0.00254	0.0037	CcSEcCtD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00252	0.01	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00251	0.00997	CbGpPWpGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00251	0.00996	CbGpPWpGaD
Atomoxetine—Somnolence—Varenicline—nicotine dependence	0.0025	0.00363	CcSEcCtD
Atomoxetine—Dyspepsia—Varenicline—nicotine dependence	0.00247	0.0036	CcSEcCtD
Atomoxetine—Decreased appetite—Varenicline—nicotine dependence	0.00244	0.00355	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00243	0.00353	CcSEcCtD
Atomoxetine—Fatigue—Varenicline—nicotine dependence	0.00242	0.00352	CcSEcCtD
Atomoxetine—Constipation—Varenicline—nicotine dependence	0.0024	0.0035	CcSEcCtD
Atomoxetine—Pain—Varenicline—nicotine dependence	0.0024	0.0035	CcSEcCtD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00239	0.0095	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TAS2R16—nicotine dependence	0.00233	0.00924	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Varenicline—nicotine dependence	0.00232	0.00337	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Varenicline—nicotine dependence	0.0023	0.00334	CcSEcCtD
Atomoxetine—NPY1R—G alpha (i) signalling events—DRD2—nicotine dependence	0.00229	0.00907	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00227	0.00901	CbGpPWpGaD
Atomoxetine—Urticaria—Varenicline—nicotine dependence	0.00223	0.00325	CcSEcCtD
Atomoxetine—Body temperature increased—Varenicline—nicotine dependence	0.00222	0.00323	CcSEcCtD
Atomoxetine—Abdominal pain—Varenicline—nicotine dependence	0.00222	0.00323	CcSEcCtD
Atomoxetine—Maprotiline—DRD2—nicotine dependence	0.00219	0.153	CrCbGaD
Atomoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00219	0.00869	CbGpPWpGaD
Atomoxetine—HTR2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00218	0.00865	CbGpPWpGaD
Atomoxetine—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00216	0.00857	CbGpPWpGaD
Atomoxetine—Methadone—OPRM1—nicotine dependence	0.00214	0.15	CrCbGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00212	0.00841	CbGpPWpGaD
Atomoxetine—Asthenia—Varenicline—nicotine dependence	0.00202	0.00293	CcSEcCtD
Atomoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00201	0.00799	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—FGD1—nicotine dependence	0.00201	0.00799	CbGpPWpGaD
Atomoxetine—Pruritus—Varenicline—nicotine dependence	0.00199	0.00289	CcSEcCtD
Atomoxetine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00199	0.00789	CbGpPWpGaD
Atomoxetine—Diarrhoea—Varenicline—nicotine dependence	0.00192	0.0028	CcSEcCtD
Atomoxetine—NPY1R—GPCR ligand binding—OPRM1—nicotine dependence	0.00191	0.00759	CbGpPWpGaD
Atomoxetine—HTR1B—brain—nicotine dependence	0.0019	0.0417	CbGeAlD
Atomoxetine—SLC6A3—brain—nicotine dependence	0.00189	0.0413	CbGeAlD
Atomoxetine—HTR2A—cardiovascular system—nicotine dependence	0.00187	0.0408	CbGeAlD
Atomoxetine—Dizziness—Varenicline—nicotine dependence	0.00186	0.0027	CcSEcCtD
Atomoxetine—HTR1D—brain—nicotine dependence	0.00184	0.0403	CbGeAlD
Atomoxetine—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.00183	0.00728	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—FGD1—nicotine dependence	0.00183	0.00725	CbGpPWpGaD
Atomoxetine—HTR2C—brain—nicotine dependence	0.00182	0.0399	CbGeAlD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00182	0.00721	CbGpPWpGaD
Atomoxetine—Vomiting—Varenicline—nicotine dependence	0.00179	0.0026	CcSEcCtD
Atomoxetine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00178	0.00704	CbGpPWpGaD
Atomoxetine—Rash—Varenicline—nicotine dependence	0.00177	0.00258	CcSEcCtD
Atomoxetine—Dermatitis—Varenicline—nicotine dependence	0.00177	0.00257	CcSEcCtD
Atomoxetine—Headache—Varenicline—nicotine dependence	0.00176	0.00256	CcSEcCtD
Atomoxetine—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.00174	0.0069	CbGpPWpGaD
Atomoxetine—SLC6A4—brain—nicotine dependence	0.00173	0.0379	CbGeAlD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00168	0.00667	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—TAS2R16—nicotine dependence	0.00167	0.00664	CbGpPWpGaD
Atomoxetine—Nausea—Varenicline—nicotine dependence	0.00167	0.00243	CcSEcCtD
Atomoxetine—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00166	0.00659	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00164	0.00651	CbGpPWpGaD
Atomoxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00163	0.00648	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00163	0.00646	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00157	0.00624	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00153	0.00606	CbGpPWpGaD
Atomoxetine—SLC6A2—brain—nicotine dependence	0.00152	0.0333	CbGeAlD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00152	0.00602	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00146	0.0058	CbGpPWpGaD
Atomoxetine—HTR2A—midbrain—nicotine dependence	0.00146	0.0319	CbGeAlD
Atomoxetine—NPY1R—GPCR ligand binding—DRD2—nicotine dependence	0.00138	0.00549	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TAS2R16—nicotine dependence	0.00138	0.00546	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00137	0.00545	CbGpPWpGaD
Atomoxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00132	0.00522	CbGpPWpGaD
Atomoxetine—Nortriptyline—DRD2—nicotine dependence	0.00132	0.092	CrCbGaD
Atomoxetine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0013	0.00516	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.00126	0.00499	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.00123	0.00489	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.00121	0.00478	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00119	0.00473	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00116	0.00459	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00113	0.0045	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.00112	0.00445	CbGpPWpGaD
Atomoxetine—Desipramine—DRD2—nicotine dependence	0.00108	0.0758	CrCbGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00108	0.00429	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—OPRM1—nicotine dependence	0.00108	0.00429	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—FGD1—nicotine dependence	0.00108	0.00428	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00107	0.00426	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00107	0.00425	CbGpPWpGaD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00107	0.00424	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00105	0.00417	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00105	0.00417	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.00102	0.00403	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00101	0.00401	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.001	0.00397	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—OPRM1—nicotine dependence	0.000982	0.0039	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKR1B10—nicotine dependence	0.000954	0.00378	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000953	0.00378	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000947	0.00375	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000943	0.00374	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000939	0.00373	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00093	0.00369	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000927	0.00368	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00092	0.00365	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00092	0.00365	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00092	0.00365	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000919	0.00365	CbGpPWpGaD
Atomoxetine—HTR2A—brain—nicotine dependence	0.000915	0.02	CbGeAlD
Atomoxetine—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000914	0.00362	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000901	0.00357	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000867	0.00344	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TAS2R16—nicotine dependence	0.00086	0.00341	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000856	0.00339	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.000853	0.00338	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.000837	0.00332	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000835	0.00331	CbGpPWpGaD
Atomoxetine—CYP2D6—brain—nicotine dependence	0.000834	0.0183	CbGeAlD
Atomoxetine—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.000819	0.00325	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000804	0.00319	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000797	0.00316	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000782	0.0031	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—DRD2—nicotine dependence	0.000782	0.0031	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000776	0.00308	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000763	0.00303	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00076	0.00302	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—FGD1—nicotine dependence	0.000743	0.00295	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.000737	0.00292	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.00073	0.0029	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.000722	0.00286	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—DRD2—nicotine dependence	0.00071	0.00282	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—OPRM1—nicotine dependence	0.000706	0.0028	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.000701	0.00278	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000697	0.00277	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000692	0.00275	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000686	0.00272	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000683	0.00271	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000676	0.00268	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—FGD1—nicotine dependence	0.000674	0.00268	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—WASF2—nicotine dependence	0.000672	0.00267	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00067	0.00266	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.000669	0.00266	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000665	0.00264	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.000655	0.0026	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000651	0.00258	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—WASF1—nicotine dependence	0.000644	0.00256	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.000633	0.00251	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000605	0.0024	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000602	0.00239	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000593	0.00235	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—OPRM1—nicotine dependence	0.00058	0.0023	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000576	0.00229	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000567	0.00225	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000559	0.00222	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00055	0.00218	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—FGD1—nicotine dependence	0.000547	0.00217	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—OPRM1—nicotine dependence	0.00052	0.00206	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—DRD2—nicotine dependence	0.00051	0.00202	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TAS2R16—nicotine dependence	0.000508	0.00201	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000507	0.00201	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000504	0.002	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.0005	0.00198	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—FGD1—nicotine dependence	0.000497	0.00197	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000496	0.00197	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000494	0.00196	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000493	0.00196	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000475	0.00188	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000452	0.00179	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.000431	0.00171	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000429	0.0017	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DRD2—nicotine dependence	0.00042	0.00166	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—OPRM1—nicotine dependence	0.000399	0.00158	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGD1—nicotine dependence	0.000398	0.00158	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000396	0.00157	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000395	0.00157	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000388	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.000387	0.00154	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—DRD2—nicotine dependence	0.000376	0.00149	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000374	0.00148	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—OPRM1—nicotine dependence	0.000362	0.00144	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.00036	0.00143	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000352	0.0014	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKR1B10—nicotine dependence	0.000352	0.0014	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000349	0.00139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000342	0.00136	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	0.000326	0.00129	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000325	0.00129	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.000294	0.00117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGD1—nicotine dependence	0.000293	0.00116	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DRD2—nicotine dependence	0.000288	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000286	0.00114	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.00028	0.00111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—OPRM1—nicotine dependence	0.000267	0.00106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DRD2—nicotine dependence	0.000262	0.00104	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.00026	0.00103	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000259	0.00103	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000255	0.00101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGD1—nicotine dependence	0.000255	0.00101	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000255	0.00101	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—WASF2—nicotine dependence	0.000248	0.000984	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000246	0.000976	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.000241	0.000956	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—WASF1—nicotine dependence	0.000238	0.000943	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.000236	0.000936	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000232	0.000919	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.000231	0.000916	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000225	0.000893	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—OPRM1—nicotine dependence	0.000214	0.000849	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD2—nicotine dependence	0.000212	0.000843	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000212	0.000843	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.000208	0.000825	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD2—nicotine dependence	0.000193	0.000765	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000184	0.000732	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—WASF2—nicotine dependence	0.000183	0.000724	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—WASF1—nicotine dependence	0.000175	0.000694	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	0.000168	0.000665	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000161	0.00064	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—WASF2—nicotine dependence	0.000159	0.000629	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—OPRM1—nicotine dependence	0.000158	0.000625	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD2—nicotine dependence	0.000155	0.000614	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.000154	0.000609	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—WASF1—nicotine dependence	0.000152	0.000603	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.00015	0.000597	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000148	0.000588	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	0.000137	0.000543	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD2—nicotine dependence	0.000114	0.000452	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD2—nicotine dependence	9.9e-05	0.000393	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2A7—nicotine dependence	9.7e-05	0.000385	CbGpPWpGaD
